Rivaroxaban Passing Into Breast Milk in Women After Childbirth
Measures how much rivaroxaban enters breast milk in breastfeeding women after childbirth.
Key facts
- Who runs it
- Thomas Jefferson University
- Where
- Philadelphia, United StatesSee the site
- Trial code
- Registry title
- Excretion of Rivaroxaban in Human Breast Milk
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 10 people, planned
- Started
- Jul 2025
- Planned end
- 31 Jul 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Rivaroxaban 10 MG Oral Tablet
- Rivaroxaban 20 MG Oral Tablet
- Record updated
- 17 July 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women within 6 weeks after giving birth who need rivaroxaban, a blood thinner, to prevent or treat blood clots. It studies how much of the drug passes into breast milk.
- Age
- Over 18 years old at the expected date of delivery.
- Sex
- Women only.
- Disease stage
- Within 6 weeks after delivery and medically stable, with no worry about ongoing blood loss. Women need a reason for a preventive dose of the blood thinner, such as a BMI of 40 or more before pregnancy or a past blood clot. Two or more of these also count: BMI 30-39 before pregnancy, being unable to move around, pregnancy problems, caesarean delivery or removal of the womb. Women can also join if their doctors say they need a full treatment dose of the blood thinner.
Main reasons for not taking part
- Being pregnant.
- A new deep vein clot or lung clot found after the birth.
- Poor kidney or liver function (creatinine clearance < 30 mL/min, or liver tests above lab normal).
- Allergy to rivaroxaban or active bleeding.
- Breastfeeding a baby who is in neonatal intensive care, was born before 37 weeks or weighed less than 2600g.
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Postpartum within 6 weeks of delivery
- Greater than 18 years old at expected date of delivery
- English speaking
- Hemodynamically stable without concern for ongoing blood loss
- Non-breastfeeding
- Or breastfeeding an infant born at or equal to 37 weeks' gestation, weighing >2600g at birth and is not requiring intensive care
- Meet inclusion criteria for prophylactic rivaroxaban dose: pre-pregnancy BMI >/= 40 and/or any personal history of VTE. Or >/= 2 of the following: pre-pregnancy BMI 30-39, immobility, pregnancy complications, cesarean delivery, hysterectomy
- Or meet inclusion criteria for therapeutic rivaroxaban dose: have an indication for therapeutic anticoagulation per the American College of Obstetricians and Gynecologists' (ACOG) practice bulletin #196, or other indication per their primary team, and recommended for such anticoagulation per their primary practitioner
Who cannot take part
- Newly diagnosed deep vein thrombosis (DVT) or pulmonary embolism (PE) in the postpartum period
- A contraindication to rivaroxaban: hypersensitivity to rivaroxaban; active pathological bleeding
- Abnormal maternal renal or liver function (creatinine clearance < 30 mL/min and/or liver function tests greater than lab normal)
- Less than 18 years old at estimated date of delivery
- Breastfeeding an infant admitted to neonatal intensive care unit, infant gestational age at birth <37w0d or weighing <2600g
- If all of the following are met: age less than 40, ambulating, body mass index (BMI) less than 30, no active history of malignancy
- Pregnant
- Hemodynamic instability and/or concern for ongoing blood loss
- If patient lacks indication for therapeutic anticoagulation in the postpartum period per the American College of Obstetricians and Gynecologists' (ACOG) practice bulletin #196
Where in United States
- Thomas Jefferson University HospitalPhiladelphia, United StatesContact: Sophie Green, MDTaking people
About the trial
What the trial wants to find out
The purpose of this study is to investigate the distribution of rivaroxaban into human milk at both therapeutic and prophylactic doses, and over time with repeated dosing.
The 2 groups in the trial
- Prophylactic rivaroxabanExisting treatment, for comparison
Patients will receive 10 mg daily of rivaroxaban starting by the first postpartum day. The medication will be ordered by their postpartum physician team through the inpatient pharmacy and dispensed by their inpatient nursing team, as per standard of care. The decision for dose 10 mg vs 20 mg of rivaroxaban is based on inclusion criteria and patient's physician team's recommendation for prophylactic (10 mg) vs. therapeutic (20 mg) dosing.
Treatment: Rivaroxaban 10 MG Oral Tablet
- Therapeutic or Intermediate dose rivaroxabanExisting treatment, for comparison
Patients will receive 20 mg daily of rivaroxaban starting by the first postpartum day. The medication will be ordered by their postpartum physician team through the inpatient pharmacy and dispensed by their inpatient nursing team, as per standard of care. The decision for 10 mg vs 20 mg of rivaroxaban is based on inclusion criteria and patient's physician team's recommendation for prophylactic (10 mg) vs. therapeutic (20 mg) dosing.
Treatment: Rivaroxaban 20 MG Oral Tablet
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Excretion of Rivaroxaban in Human Breast Milk
- Plain-language title
- Rivaroxaban Passing Into Breast Milk in Women After ChildbirthGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 17 July 2025